MOESM6 of Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

  • Chia Hung Chien (Contributor)
  • Jian-Ying Chuang (Contributor)
  • Shung-Tai Yang (Contributor)
  • Wen-Bin Yang (Contributor)
  • Pin Yuan Chen (Contributor)
  • Tsung-I Hsu (Contributor)
  • Chih Yuan Huang (Contributor)
  • Wei-Lun Lo (Contributor)
  • Ka-Yen Yang (Contributor)
  • Ming Sheng Liu (Contributor)
  • Jui Mei Chu (Contributor)
  • Pei Hsuan Chung (Contributor)
  • Jr Jiun Liu (Contributor)
  • Shao Wen Chou (Contributor)
  • Shang Hung Chen (Contributor)
  • Kwang Yu Chang (Contributor)



Additional file 6: Figure S6. DETC inhibitor used in vitro and in vivo. (A) (Left) U87MG spheres were treated with different doses of DETC as indicated. The cell lysates were analyzed via western blot. The statistic results (Right) were shown. (B) Mice that received U87MG-r#10 cells were randomly treated with TMZ or TMZ/DETC for 5 consecutive days. Representative images of IHC staining in which the specific protein levels of the resistant xenografts were analyzed. *Pâ
可用日期1月 1 2019
發行者Unknown Publisher